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Abstract
Diabetes mellitus is a chronic disease that affects hundreds of millions of people worldwide. Type 1 diabetes 
(T1D) is characterized by the lack of pancreatic b-cells that had been destroyed as a result of an autoimmune 
response. Therefore, in patients with T1D, the replacement therapy with functional b-cells derived from extrinsic 
sources could be a preferable option as compared to insulin treatment. Unfortunately, successful transplantation 
of whole pancreata or pancreatic islets into patients with diabetes is available only to a fraction of them due to 
the scarcity of donors. The rapid development of cell reprogramming methods made it possible to generate large 
numbers of human b-like cells derived from human embryonic stem cells (hESCs) or human induced pluripotent 
stem cells (hiPSCs). This review describes the basis of in vitro differentiaton protocols of b-like cells that mimic 
changes of the main signaling pathways during the key stages of human and murine pancreas development, 
which are described first. During the last 15 years it was found that there are no important differences between 
hESCs and hiPSCs in their differentiation capacities into b-like cells and the expression profiles of the key tran-
scription factors. The in vitro produced b-like cells are immature as demonstrated by functional tests in rodents 
and single-cell transcriptomic and proteomic analyses. After the transplantation of the b cell progenitors into 
immunocompromised diabetic mice, a few weeks have to pass before the increased insulin levels in response 
to glucose load appear. There is a continuous progress in the development of open-type encapsulation devices 
which allow the vascularization of the transplanted cells and protect them against host’s immune cells. The re-
sults of the first clinical trial of human partially differentiated endocrine progenitors of b cells transplanted into 
patients with T1D will be published in the year 2019. It is hoped that further improvements in the techniques 
of large-scale generation of the b-like cells derived from human pluripotent stem cells will bring us closer to 
their clinical application as a form of cause-directed therapy for people with diabetes. (Folia Histochemica et 
Cytobiologica 2019, Vol. 57, No. 1, 1–14)
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Abbreviations*:
Arx — aristaless-related homeobox; bFGF — basic fibro-
blast growth factor; bHLH –— basic helix-loop-helix family; 
BMP — bone morphogenetic protein; Cdx2 — caudal-type 
homeobox transcription factor 2; c-Myc — v-Myc avian 
myelocytomatosis viral oncogene homolog; CPA — car-
boxypeptidase A; CXCR4 — chemokine (C-X-C motif) 
receptor 4; DE — definitive endoderm; DLL1 — delta-like 
canonical Notch ligand 1; Dpc — day post conception; EP 
— endocrine progenitor; EGF — epidermal growth factor; 
ESC — embryonic stem cell; Ex4 — exendin-4; FACS 
— fluorescence-activated cell sorting; FGF — fibroblast 
growth factor; FoxA1, -2 — forkhead box A1, -2; Gata4 — 
GATA-binding protein 4; Gata6 — GATA-binding protein 
6; Glis — Gli similar family of transcription factors; GSIS 
— glucose-stimulated insulin secretion; GSK3b — glucagon 
synthase kinase 3b; hESC — human embryonic stem cell; 
Hnf4 — hepatocyte nuclear factor 4; Hnf6 — hepatocyte 
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nuclear factor 6, synonym — Onecut1; hPSC — human 
pluripotent stem cell; hiPSC — human induced pluripotent 
stem cell; IDE1/2 — inducers of definite endoderm 1/2; 
Idx1 — islet/duodenum homeobox 1, synonym of Pdx1; 
IGF-1 — insulin-like growth factor 1; Ins — insulin; Ipf1, 
insulin promoter factor 1, synonym of Pdx1; iPSC — in-
duced pluripotent stem cell; Irx1 — iroquois homeobox 
protein 1; Isl1 — LIM homeobox 1; KGF — keratinocyte 
growth factor; Klf4 — Krüppel-like factor 4; Ldb1-Isl1 — 
LIM domain-binding protein 1–islet 1; MafA, -B — avian 
musculoaponeurotic fibrosarcoma oncogene homolog-A 
or -B; Mesi1 — Meis homeobox 1; Mist1- bHLH family mem-
ber, a15; N0); Mnx1 — motor neuron and pancreas homeo- 
box 1; MPC — multipotent progenitor cell; MPP — multipo-
tent pancreatic progenitor; NeuroD1 — neurogenic differ-
entiation factor 1; Neurog3 — neurogenin 3; Ngn3, acronym 
for Neurog3; Nkx2.2 — Nirenberg and Kim homeoboxfactor 
2.2; Nkx6.1 — Nk6 homeobox protein 1; Oct4 — octamer 
binding transcription factor 4; Onecut — synonym of Hnf6; 
Pax4, -6 — paired box homeodomain transcription factor 4, 
-6; Pdx1 — pancreatic and duodenal homeobox 1 transcrip-
tion factor; PKC — protein kinase C; PSC — pluripotent 
stem cell; Ptf1a — pancreas transcription factor 1 subunit 
alpha; RA — retinoic acid; Rbpj — Ras-associated protein 
Rap1; Rfx — regulatory factor X; Shh — sonic hedgehog; 
Sox9, -17 — sex-determining region Y box 9, -17; SUSD2 
— Sushi domain containing 2; T1D — type 1 diabetes; Tcf1 
— transcription factor 12; TGF-b — transforming growth 
factor b; Wnt3 — wingless-type MMTV integration site 
family, member 3. 
Introduction 
Diabetes mellitus (DM) is a chronic metabolic dis-
ease that currently affects more than four hundred 
millions of people worldwide [1]. DM is caused by 
a nearly absolute lack of insulin in type 1 diabetes 
(T1D) patients or an insufficient release of insulin 
in type 2 diabetes (T2D) related to insulin resistance 
of peripheral tissues, mainly, but not only, due to in-
creased body and fat mass in obese patients. T1D is 
usually caused by autoimmune mechanisms that result 
in the reduction of b cells’ number in pancreatic islets. 
The pathogenesis of T2D is based on the overload of 
b cells by the resistance of the peripheral tissues, such 
as skeletal muscles and fat cells, to insulin’s action 
caused by increased serum levels of free fatty acids 
and oxidative stress in pancreatic islet cells. Although 
for almost one hundred years exogenous insulin has 
been administered to T1D patients as a substitute of 
the endogenous hormone, the lifelong treatment does 
not affect the cause of the disease and may be asso-
ciated with many complications of which episodes of 
hypoglycemia are most important. T2D is treated by 
drugs that increase the secretion of insulin, its tissue 
sensitivity, improve glucose disposal, or delay glucose 
absorption in the gastrointestinal tract. However, in 
many T2D patients the exhaustion of b cells even-
tually occurs and leads to the additional treatment 
with insulin. The best causative treatment for T1D 
would be to increase the number of functional b cells. 
This has been in fact achieved in a relatively small 
number of patients, either through transplantation 
of cadaver-derived whole pancreas, pancreatic islets, 
or infusion of isolated b cells into gastrointestinal 
venous system of recipients. These treatment options 
are available in many developed countries; however, 
to a limited extent only. The main limitation, similarly 
as with transplantation of other organs, is the scarcity 
of donor tissues, which makes the allotransplantation 
options practically unavailable to the majority of 
patients with DM. Moreover, the transplanted islets 
require lifelong immunosuppression which poses 
further health problems. 
The continuous progress of molecular and cell 
biology techniques makes it possible to generate 
in vitro human functional b cells and introduce them 
into diabetic patients to increase endogenous insulin 
production in response to changes in blood glucose 
concentrations. In this short review we will describe 
the methods that have been developed not only to pro-
duce ex vivo b-like cells but also to efficiently protect 
them from an immune attack after transplantation 
into diabetic patients (the term ‘b-like cell’ is here de-
fined as an insulin-positive cell that contains secretory 
granules; however, it does not imply presentation of 
the same functional characteristics as primary human 
b cell). There are two main sources for the in vitro 
generation of human b-like cells: (i) human embryonic 
stem cells (hESCs) and human induced pluripotent 
stem cells, both referred further as pluripotent stem 
cells (hiPSCs), and (ii) differentiated cells from 
various organs that can be transdifferentiated into 
b-like cells, mainly by genetic manipulations. It seems 
obvious that the obtained b-like cells should express 
molecular markers of normal b cells such as a set of 
specific transcription factors and other molecules 
that characterize mature b cells as a result of terminal 
differentiation. Moreover, after transplantation into 
animals with experimentally-induced diabetes or 
into patients with diabetes, these ex vivo generated 
b-like cells should present features of functional ma-
turity such as rapid alterations of intracellular Ca2+ 
concentration and secretion of insulin in response to 
changing glucose levels. 
*Since originally most of the transcription factors have been detected and 
described in Drosphila and non-human vertebrates, their abbreviations 
are written in small letters.
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The elucidation of the molecular background of 
the stages of pancreas development in mouse and 
humans laid solid foundations for the implementation 
of cell and molecular biology techniques to transform 
hESC, hiPSC, or normal somatic cells into functional 
b-like cells, processes often termed collectively as ‘cell 
reprogramming‘. This paper will provide an overview 
of the progress in the field of the in vitro b cell neogen-
esis from pluripotent stem cells as a potential source 
of insulin-secreting cells for patients with diabetes. 
Since the protocols for obtaining in vitro b-like cells 
from human PSCs to a great extent recapitulate the 
embryonic stages of pancreas development, a short 
review of the factors that control the development of 
human (and murine) pancreas, and especially b cells, 
will be first provided. 
The embryonic development  
of the pancreas and its driving forces 
The development of pancreas is, in general, very sim-
ilar in many vertebrate species. Since the availability 
of early human embryos for studies is limited, the 
knowledge about the mechanisms of the embryonic 
development of pancreas in mouse (and other ver-
tebrates) could be generally transposed to the early 
stages of pancreatic development in humans. The 
genetic manipulations in mice allowed for the iden-
tification of multiple transcription factors which in 
a complex but coordinated way control the develop-
ment and growth of the pancreas. Many, although not 
all, of these transcriptions factors were shown to play 
a key role in human pancreatic development. Moreover, 
in transgenic mice it was possible to perform lineage 
tracing experiments that enabled to characterize 
the developmental history of the major cell types 
of endocrine and exocrine parts of the pancreas [2]. 
This knowledge has been used by many groups to 
mimic in vitro the developmental pathway of b cells 
in a step-wise differentiation of hESC or hiPSCs into 
insulin-secreting b cells, and also other pancreatic 
islets’ cell types of which a, d, e, and PP cells secrete 
glucagon, somatostatin, ghrelin, and pancreatic poly-
peptide, respectively.
 
In mammals pancreatic development begins in two 
distinct areas that later fuse in one organ. In mouse 
during gastrulation the flat definitive endoderm folds 
to form primitive gut tube in which foregut, midgut, 
and hindgut can be recognized. The foregut is divided 
into the anterior part that gives rise to the thymus, 
thyroid, parathyroid, and lungs, and the posterior 
foregut. The evaginations of the posterior foregut 
appear at the embryonic day 9 (E9d) as a dorsal 
pancreatic bud (at the junction with midgut) and as 
the ventral bud at E9.5d [3, 4]. Due to the gut rota-
tion at E12–13d, the ventral and dorsal buds become 
adjacent and fuse with each other. There are two 
developmental phases during pancreas development 
in mouse. During the primary transition (E9.5–12.5d) 
there is massive proliferation of pancreatic progenitor 
cells forming stratified epithelium in which several 
micro-lumen structures develop that later fuse [3, 
5–7]. At this stage few endocrine cells appear that 
are mainly polyhormonal, expressing both glucagon 
and insulin, and some monohormonal cells; however, 
these cells probably do not commit to mature islets 
[3, 8]. During the secondary transition from E13.5d to 
E16.5d microlumens fuse to create the characteristic 
tubular structures lined by pancreatic epithelium in 
a form of plexus that branches further into a continuous 
epithelial network, segregated into tip and trunk do-
mains [7, 9, 10]. At this stage of pancreatogenesis the 
proliferation of endocrine progenitor cells is extensive 
and all five types of endocrine cells are generated 
[3]. The pancreatic acini originate from distal tip 
cells whereas the trunk cells will differentiate into 
ductal and endocrine cells [3, 7, 11]. The extensive 
proliferation of pancreatic epithelium is accompanied 
by the differentiation of endocrine progenitors into 
neurogenin 3 (Ngn3)-positive cells followed by the 
formation of mature endocrine cells [12–14]. 
In comparison to the bulk of data on early embryo-
genesis in model non-human species such as mouse 
and chick, the information about the early stages of 
human development, and of pancreas in particular, is 
limited, mainly due to the scarcity of the early human 
embryos (< 8 weeks of gestation, G8w) available for 
investigations. However, similarly as in mouse, the 
differentiation of the human endoderm into b cells 
can be classified into the following pivotal stages: (i) 
definitive endoderm (DE), (ii) primitive gut tube, 
(iii) foregut endoderm, (iv) pancreatic anlagen com-
posed of multipotent progenitor cells (MPCs) that 
will differentiate into the three major pancreatic cell 
lineages, i.e. exocrine, ductal, and endocrine cells, (v) 
endocrine progenitors, and (vi) b cells [15–18]. 
Pan and Brissova [16] and Jennings et al. [17] 
compared the stages of human pancreas develop-
ment, its key features, and estimation of an equivalent 
timeline of the mouse pancreas development. At the 
gestational day 25–27 (G26–27d), i.e. at the Carnegie 
stages 9–10 (CS9–10), the transient contact of the 
notochord (and dorsal aortae) with the pre-pancre-
atic endoderm suppresses the expression of the sonic 
hedgehog (SHH) pathway. This induces folding of the 
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posterior foregut-derived definitive endoderm which 
results in the formation of the pancreatic dorsal bud at 
G26d that is followed by the formation of two ventral 
buds at G30d (CS12–13) [15, 17]. The left ventral bud 
gradually regresses and the right ventral bud migrates 
backwards at G35d (CS15) as a result of gut rotation 
and finally fuses with the dorsal bud at gestational 
weeks 6–7 (G6–7w, CS18–20) to form a single organ 
with the main pancreatic duct formed by the coales-
cence of the dorsal and ventral ducts [15]. In humans 
the dorsal pancreatic bud will form the major part of 
the head, the body, and the tail of the future pancreas 
whereas the right ventral bud will form the inferior 
part of the head and uncinate process [4]. Between 
G35d and G45d (CS15 and CS19, respectively) an 
extensive growth of the pancreatic anlagen leads to 
the formation of ductal branching and appearance of 
microlumens in the acinar cell compartment as well 
as extensive proliferation of multipotent progenitor 
cells. At G7w (CS19) tip-trunk compartmentaliza-
tion becomes distinguishable: populations of tip-like 
cells will differentiate into exocrine acini whereas 
the trunk-like cells will develop into endocrine and 
ductal cells [16, 17]. 
These morphogenetic processes are initiated 
and controlled by transcription factors and signaling 
molecules that activate or suppress basic signaling 
pathways such as WNT, SHH, and Notch (discussed 
in 11, 15, 18, 19). At G30d (CS12) the expression of 
the crucial transcription factor PDX1 (pancreatic and 
duodenal homeobox 1), the earliest pancreas-specific 
transcription factor, can be detected in the endoderm 
differentiating into pancreatic anlagen [15], similarly 
as during mouse embryogenesis in the pancreatic 
endoderm [5, 6, 11]. Soon thereafter, the expression 
of other transcription factors: SRY (sex-determining 
region Y)-box 9 (SOX9), GATA4 (Gata-binding pro-
tein 4), and NKX6.1, necessary for human pancreatic 
development, takes place [15, 20]. 
Similarly as in mouse, the expression of the 
NEUROG3 transcription factor is a sign of the 
beginning of the endocrine commitment [21] that 
is further controlled by the expression of other tran-
scription factors. At G7.5w (CS21) the first endocrine, 
insulin-positive cells appear, and at G9w glucagon–
expressing a cells emerge [15, 21–23]. At G10w the 
delamination and endocrine cell clustering starts so 
that at G12-13w all types of endocrine cells are present 
in the developing islets [15, 16, 21, 22]. 
The role of numerous transcription factors that 
induce and control the development of the pancreas 
by the regulation of gene expression during the sub-
sequent stages of pancreas development has been in 
depth characterized in mouse [11, 18, 19, 24]. They 
were found, although with few exceptions, to play 
a similar role during the development of human pan-
creas [15, 17, 25]. In mouse the differentiation of the 
multipotent progenitor cells into exocrine, endocrine, 
and ductal lineages of the adult pancreas is regulated 
by the coexpression of the key transcription factors 
such as Pdx1, Ptf1a, Foxa2, Sox9, Nkx6.1, and the 
presence of carboxypeptidase 1A (Cpa) [6, 11, 18, 
24]. The development of the ductal/endocrine lin-
eages from MPCs is associated with the loss of Ptf1a 
and maintenance of Nkx6.1 expression, whereas the 
development of the exocrine compartment depends 
on the downregulation of Nkx6.1 and continued ex-
pression of Ptf1a [26]. The differentiation of b cells 
is controlled by the Pdx1 transcription factor which 
promotes specification and maturation of MPCs into 
pancreatic b cells in concert with the other transcrip-
tion factors such as neurogenin 3 (Ngn3), Nkx6.1, 
and MafA [6, 18]. Many of the transcription factors 
that control the development of the murine pancreas 
were identified during the stages of human pancreas 
differentiation [13, 15, 25] and are shown in Figure 1. 
The role of some transcription factors that are crucial 
for the pancreatogenesis will be shortly characterized. 
In humans PDX1, also called insulin promoter 
factor 1 (Ipf1) or islet/duodenum homeobox 1 (Idx1), 
a marker of early MPCs, is detected at G30d (CS12) 
in a presumptive pancreatic endoderm even before 
pancreatic bud formation from definitive endoderm 
takes place [15]. PDX1 plays a pivotal role in the 
differentiation of all pancreatic cell types, as Pdx1 
knockout mice exhibit pancreatic agenesis [27]. The 
role of PDX1 in the human pancreatic development 
was confirmed when a neonate presented lack of 
exocrine pancreas function and insulin-requiring 
hyperglycemia caused by a homozygous point de-
letion resulting in a frame shift [28]. Direct lineage 
tracing studies in mouse showed that Pdx1-expressing 
progenitors in the early mouse embryo give rise to 
all pancreatic cells types, i.e. ductal, exocrine, and 
endocrine cells, and that the progenitors for the ma-
ture pancreatic ducts separate from the endocrine/ 
/exocrine tissues before the E12.5 [2]. In the pancreatic 
endocrine cells Pdx1 is expressed mainly in the b cells 
where it binds to and activates the insulin promoter 
and increases insulin gene transcription. Larsen and 
Grappen-Botting [11] presented a graphical overview 
of the interconnectivity of the pancreatic progenitor 
gene regulatory network at the early stages of mouse 
pancreatic development, with the Pdx1, Ptf1a, Foxa2, 
and Sox9 transcription factors as the key nodes. 
A recent genome-wide analysis of the in vitro generated 
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human pancreatic progenitor cells by the Chip-seq for 
PDX1 revealed a total of 8088 PDX1-bound regions 
that map to 5664 genes. The PDX1 target regions 
include important pancreatic transcription factors 
such as PDX1 itself, RFX6, HNF1B, and MEIS1 as 
well as signaling molecules and factors important 
for b cell function [29]. Moreover, the application of 
the ChIP-seq technique for PDX1 disclosed several 
novel PDX1 target genes including RFX3, required 
in mouse for the differentiation and function of the 
b cells, and the ligand of the Notch receptor DLL1, 
which is important for endocrine induction [29]. 
The PTF1A (pancreas transcription factor 1 sub-
unit alpha) gene on human chromosome 10 encodes 
a transcription factor with a key role in early human 
pancreas development and cerebellar neurogenesis 
[26, 30]. The transcripts of the PTF1A have been 
demonstrated during the development of human pan-
creas; however, in contrast to mouse, the presence of 
PTF1A protein has not been demonstrated in humans 
yet, probably due to the lack of available antibodies 
[17]. In mouse acinar differentiation is regulated by 
a set of transcription factors including Ptf1a and Mist1 
[31]. Ptf1a (p48) is an important bHLH factor that 
forms a complex with Tcf12 and Rbpjl, which allows 
the expression of genes for the secretory enzymes 
present in the mature acini [32]. It is coexpressed with 
Pdx1 in both dorsal and ventral pancreatic buds from 
E9.0 to E9.5, and later, at E12.5, Ptf1a expression is 
found in growing tips of the branching epithelium to 
eventually end up in the acinar cells [6]. 
Neurogenin 3 (NEUROG3, NGN3) belongs to 
a family of basic helix-loop-helix (bHLH) transcription 
factors involved in the development of central nervous 
system and embryonic pancreas. Neurog3 is transient-
ly expressed in mouse [7, 33] and human pancreatic 
endocrine progenitor cells [15]. In mouse, there are 
two phases of Ngn3 expression, i.e. during the first 
and second transition, the latter peaking at E15.5 
[7]. Ngn3 is required for endocrine differentiation, as 
demonstrated by the complete lack of all types of pan-
creatic endocrine cells in Neurog3-deficient mice [12]. 
Ngn3 initiates the differentiation of Pdx1-expressing 
progenitor cells and activates the expression of addi-
tional transcription factors important for the differ-
entiation of MPCs into endocrine cell lineages [12]. 
In mouse single-cell lineage tracing has shown that a 
and b cells originate from different Neurog3-express-
ing endocrine cells [12]. NGN3 expression during 
human pancreatic development starts from G8w with 
Figure 1. The expression of key transcription factors (TFs) at the sequential stages of the human definitive endoderm dif-
ferentiation into pancreatic lineages of acinar, ductal, a and b cells. The capital letters denote human TFs which were first 
detected at the respective phases of pancreas differentiation in mouse. adetected as transcripts in human embryos. Abbrevi-
ations are explained past the Abstract. Based on the data summarized by Jennings et al. [17], Al-Khawada et al. [19], Lyttle 
et al. [22], Riedel et al. [23], Conrad et al. [25], and Santosa et al. [41].
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a peak at the end of the first trimester [15], concom-
itantly with the development of islets which at G12-
13w contain a, b, d, and g cells [15, 20]. The NGN3 
expression tightly correlates with the appearance of 
fetal insulin-containing b cells; however, it becomes 
undetectable after G35w [34] and is not present in 
mature human endocrine cells [17, 22]. Interestingly, 
in humans NEUROG3 may not be required for the 
development of the endocrine pancreas since the pa-
tients with NGN3 mutation were born with circulating 
C-peptide [35]. In mouse, apart from Ngn3, Pax4 
and Arx transcription factors are important for the 
determination of endocrine cell fate [6, 36]. NGN3 
is also critical for human pancreatic endocrine devel-
opment since null mutations in NGN3 cause neonatal 
diabetes and block b cell differentiation from human 
pluripotent stem cells [37].
NKX6.1 (NK6 homeobox protein 1) and NKX2.2 
transcription factors are expressed in pancreatic endo-
derm and endocrine precursor cells and are essential 
for promoting b cell specification by controlling cell 
lineages between endocrine and acinar cell fate. In 
mouse the expression of Nkx6.1 is required for the 
development of the b cell lineage from endocrine 
progenitors [38] so that Nkx6.1 is specifically expressed 
in adult b cells. In humans the expression of NKX6.1 
follows that of PDX1 and SOX9 and takes place prior 
to the transient activation of NGN3 that is necessary 
for the differentiation of b and other islet endocrine 
cell types [17]. However, a recent single-cell gene ex-
pression analysis of human ESCs differentiation into 
b cell lineage revealed that the activation of NKX6.1 
can be initiated before or after endocrine commitment 
(downstream of NGN3 expression) without negative 
effect on the generation of b-like cells in vitro [39].
 
MAFA (v-Maf musculoaponeurotic fibrosarcoma 
oncogene homolog A) is a key transcription factor for 
fetal b cell maturation. Nearly no MAFA is detect-
ed in human embryo until gestational week 21, and 
its expression gradually increases after birth, being 
limited at adult age to b cells [21]. This transcription 
factor binds to the enhancer/promoter region of the 
insulin gene RIPE3b/C1-A2 and activates insulin gene 
expression in response to glucose [40, 41]. 
In addition to the transcription factors mentioned 
above, there are many other which participate in the 
control of the maintenance and expansion of multipo-
tent pancreas progenitors and endocrine progenitors 
(Fig. 1). Their function and interdependency, revealed 
mainly in the studies of mouse pancreas development, 
have been extensively reviewed by Jørgensen et al. [6] 
and other authors [5, 11, 18, 19, 41–43].
Although the development of the human pancreas 
generally recapitulates the stages of mouse pancreas 
differentiation, there are some important interspecies 
differences which can affect the strategies for the in 
vitro b cell differentiation, as summarized by Jennings 
et al. [17], Nair and Hebrok [44], and Balboa et al. [45]. 
For instance, the expression of the key transcription 
factor PDX1 necessary for the development of pan-
creatic progenitor cells occurs in the human endo-
derm later than in mouse, i.e. after gut closure once 
mesenchyme has separated notochord and aorta from 
dorsal foregut [15]. The expression of neurogenin 3 is 
biphasic during murine pancreatogenesis [7] but not in 
humans [15]. Other differences refer to the different 
timing of the expression of the transcription factors 
GATA4, SOX17, and NKX2.2 [6, 15]. For example, 
the expression of GATA4 is delayed in human pan-
creatic development, and SOX17, a definitive endo-
derm marker which exists in the presumptive human 
pancreatic endoderm, is lost in rodent pancreatic 
epithelium [15]. In the mouse, pancreatic islets are 
formed only close to birth (E19–21) whereas in hu-
man embryos islets appear at G12w [15]. Moreover, 
b cells are the first endocrine cells detected in human 
pancreas [15, 20, 22] in contrast to mouse, with a cells 
forming first [33]. In mouse there are two phases of 
the appearance of endocrine cells during pancreatic 
development, referred to as primary and secondary 
transition, respectively. In human embryos no early 
pancreatic endocrine differentiation takes place 
so that only one wave of endocrine differentiation 
takes place [3, 15, 34]. Whereas in the developing 
human pancreas the NKX2.2 transcription factor is 
not expressed in multipotent pancreatic progenitor 
cells [15] (Fig. 1), Nkx2.2 is widely expressed in the 
murine pancreatic bud until E13 when its expression 
becomes restricted to the Ngn3-positive cells [46]. 
MafB expression is lost postnatally from mouse [11] 
but not human [23] b cells.
In a landmark study, Jennings et al. [47] used la-
ser capture, RNA amplification, and computational 
analysis of deep sequencing to reveal the transcrip-
tomic programs regulating the earliest development 
of pancreas, liver, and biliary tree in human embryos. 
They found that pancreas-enriched gene expression 
was less conserved between human and mouse than 
for the liver. Apart from confirming that the dorsal 
pancreatic bud was enriched for components of 
Notch, Wnt, BMP, and FGF signaling, they discov-
ered over 30 transcription factors which have yet not 
been associated with the differentiation of pancreatic 
endoderm [47]. Altogether, the reported differences 
between some stages of b cells differentiation in 
mouse and human (and generally between mature 
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endocrine cells in the murine and human pancreata, 
not mentioned in this review) suggest caution when 
relating findings from mice to humans. It is expected 
that further development of computational algorithms 
will allow using the transcriptomic and proteomic 
data derived from the studies of human embryos to 
facilitate stem cell research and clinical interpretation 
without inter-species extrapolation.
The elucidation of the chronology and hierarchy 
of the signaling events during mouse and human 
pancreas development, apart from its pure scientific 
importance, together with the breakthrough technol-
ogies of human embryonic stem cells’ differentiation 
and human induced-pluripotent stem cells made it 
possible to generate large numbers of multipotent 
pancreatic progenitor cells that could be further 
differentiated in vitro, and after transplantation into 
immunocompromised diabetic mice develop and ma-
ture into insulin-secreting b-like cells, possibly also in 
humans with diabetes. 
In vitro recapitulation of the developmental 
stages of pancreas enables the reprogramming 
of hESCs or human iPSCs into  
insulin-secreting cells
The progress in the understanding of the molecular 
mechanisms of pancreas development, together with 
the advent of techniques of human ESCs differenti-
ation [48] and generation of mouse [49] and human 
[50, 51] induced-pluripotent stem cells made it pos-
sible to produce in vitro b-like cells with the aim of 
replacing dysfunctional or lacking b cells in patients 
with diabetes. Both types of pluripotent stem cells 
express unlimited proliferation capacity in vitro and 
may differentiate under appropriate culture condi-
tions into virtually any cell type. Thus, they offer new, 
fascinating possibilities of future treatment of patients 
with diabetes by the transplantation of in vitro gener-
ated insulin-secreting cells. Generally, the strategies 
for the generation of functional b-like cells are based 
on mimicking in vitro the developmental stages of in 
vivo pancreas and b cell development by the exposition 
of the sequentially cultured differentiating hESCs or 
human iPSCs (hiPSCs) to empirically determined 
cocktails of various key growth factors and small 
molecules which temporally activate transcription 
factor cascades and signaling pathways specific for the 
phases of definitive endoderm, pancreatic endoderm, 
pancreatic progenitors, endocrine progenitors, and 
finally of b cell lineage differentiation (Fig. 2).
Currently, two basic strategies have been pursued 
for the production of b-like cells for cellular replace-
ment therapy for patients with diabetes: (i) in vitro 
differentiation of hESCs or hiPSCs, and (ii) in vitro 
transdifferentiation of differentiated somatic cells, of-
Figure 2. Main stages of an idealized, simplified protocol of the differentiation of hESCs or hiPSCs into b-like cells. The major 
markers of the differentiation stages are shown above and the growth factors and other molecules controlling the signaling 
pathways directing definitive endoderm cells’ transformation into b cell lineage are shown below the presented developmental 
stages (based on data presented in (59–64, 67–71). Abbreviations as listed on page 1 and: ALK5iII — activin receptor-like 
kinase 5 inhibitor II; Axl — receptor tyrosine kinase; CHIR99021 — a selective GSK3b inhibitor; inh — inhibitor; N-cys — 
N-acetyl cysteine; SANT1 — Shh antagonist; T3 — triiodothyronine; wortmannin — phosphoinositide 3-kinase inhibitor. 
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ten, but not exclusively, of endodermal origin, without 
reverting to the pluripotent stage through gene manip-
ulation [52]. The second option will not be described 
in this short review. However, it has to be noted that 
the ultimate target of both approaches is the effective 
functioning in patients with diabetes of insulin-secret-
ing cells able to produce adequate amounts of insulin in 
response to the rapid changes of blood glucose levels.
Human embryonic stem cells obtained from the 
inner cell mass of human blastocysts [48] have been 
investigated extensively as pluripotent stem cells for 
the in vitro generation of many cell types. Scientists 
from the laboratory of CyThera (later Novocell, Inc., 
and currently ViaCyte, Inc.) described a method of ef-
fective hESC differentiation into definitive endoderm 
(DE) cells [53]. A year later they developed the first 
highly replicable multi-step protocol of the differen-
tiation of the DE cells into pancreatic endocrine cells, 
which was based on mimicking pancreas development 
through the stages of primitive gut tube, posterior 
foregut, pancreatic endoderm and endocrine pro-
genitor cells. They obtained polyhormonal cells that 
expressed insulin and other pancreatic hormones; 
however, these cells did not respond to increased 
glucose levels by enhanced insulin secretion [54]. 
After improving the in vitro differentiation protocol, 
the same group showed that after transplantation of 
hESC-derived immature pancreatic endoderm cells 
(pancreatic progenitors expressing both PDX1 and 
NKX6.1 transcription factors) into immunodeficient 
mice with experimentally-induced diabetes, normogly-
cemia was restored after 3–4 months, which suggested 
that this time was needed for the in vivo differentiation 
and maturation of these cells into glucose-responsive 
insulin-secreting cells [55]. These early protocols of 
hESC differentiation presented low efficiency, lasted 
for many weeks, and resulted in a heterogeneous 
population of insulin-immunoreactive cells that were 
often polyhormonal [54–56]. After improving many 
stages of hESC differentiation into insulin-secreting 
cells, a few years ago the ViaCyte started the first clin-
ical phase I/II trial involving hESCs-derived immature 
pancreatic progenitor cells co-expressing PDX1 and 
NKX6.1 (PEC-01 cells) in patients with T1D (Clin-
icalTrials.gov identifier: NCT02239354, trial VX-1). 
These cells were placed in immunoprotective capsules 
and implanted under the skin of the patients. Initial 
data from clinical evaluation of the safety, long-term 
tolerability and efficacy of this system is expected to 
be published in the middle of the year 2019. Two years 
ago ViaCyte initiated two other clinical trials to test 
a new macroencapsulation device (“open Encaptra 
Device”) in which direct vascularization of the PEC-
01 cells can take place (ClinicalTrials.gov identifiers: 
NCT03162926 and NCT03163511). Although the use 
of the differentiated ESCs bears the risk of teratoma 
formation as found in diabetic mice [57], so far can-
cers have not been reported in the T1D patients who 
participate in the ViaCyte trials (www.viacyte.com). 
In January 2019, the Center for Beta Cell Therapy 
in Diabetes and ViaCyte announced the start of the 
European clinical trial of PEC-Direct known also 
as VC-2, an encapsulated pancreatic progenitor cell 
product designed to replace lost insulin-producing b 
cells in patients with T1D (www.betacelltherapy.org).
The technique of de-differentiation of somatic 
cells by transcription factors’-based somatic cell re-
programming was first demonstrated for mouse adult 
fibroblasts by Takahashi and Yamanaka [49] who used 
retroviral transduction with Oct3/4, Sox2, c-Myc, and 
Klf4, and soon afterwards was used for the repro-
gramming of human dermal fibroblasts by retroviral 
transduction with POUF51 (OCT-4), SOX-2, KLF4, 
and MYC [50]. The lentiviral transduction of human 
fetal fibroblasts with OCT-4, SOX-2, NANONG, 
and LIN28 was sufficient for the generation of hu-
man induced pluripotent stem cells that had normal 
karyotypes, expressed telomerase, and maintained 
the developmental potential to differentiate into 
advanced derivatives of all three primary germ layers 
[51]. The use of hiPSCs which exhibit the morphology 
and growth properties of ESCs obviates the need for 
human embryos to obtain ESCs for in vitro differ-
entiation programs into almost all types of somatic 
cells. Similarly to the differentiation of hESCs, the in 
vitro generation of b-like cells from hiPSCs is based 
on the sequential modulation of multiple signaling 
pathways controlling pancreas development, which 
has been best characterized in mouse [11], however, 
only partially in humans [15–17]. Substantial prog-
ress in the in vitro production of large numbers of b 
cell progenitors was achieved by the introduction of 
improved ‘second generation’ protocols for differen-
tiation of human ESCs [58] or human iPSCs [59, 60] 
into b-like cells. The protocol described by Rezania 
et al. [58] comprised 7 stages: 1. hESCs or hiPSCs, 2. 
Definitive endoderm, 3. Primitive gut tube, 4. Poste-
rior foregut, 5. Multipotent pancreatic progenitors, 6. 
Endocrine progenitors, 7. Immature endocrine cells, 
8. b-like cells. These in vitro differentiation steps are 
promoted and controlled by various empirically-de-
fined sets of factors known to affect many signaling 
pathways of the respective stages of the developing 
pancreas in mouse and humans [11, 17–19, 24, 26, 
41–45]. There have been numerous modifications 
of the differentiation protocols of hESCs or hiPSCs 
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into b-like cells aimed at the production of large 
populations of relatively pure multipotent pancreatic 
progenitors (enriched in PDX1 and NKX6.1 cells) 
which can be further induced into monohormonal, 
insulin-secreting and glucose-responsive cells. Pa-
glucia et al. [59] used large-scale floating cell culture 
system for the differentiation of hESCs and hiPSCs 
by the use of a combination of 11 small molecules 
to obtain b-like cells through the stages of definitive 
endoderm, posterior gut tube, and early pancreatic 
progenitor cells. After 4–5 weeks, with efficiency 
higher than 30%, they obtained glucose-responsive, 
monohormonal insulin-producing cells that showed 
typical ultrastructure of b cells and co-expressed key 
b cell markers, including high mRNA levels of the 
transcription factor MAFA. Two weeks after the 
transplantation of these partially differentiated cells 
into immunodeficient diabetic NRG-Akita mice, 
a model of diabetes [61], normalization of blood glu-
cose level was observed [59]. Ma and Zhu [62] have 
graphically summarized three improved protocols 
[59–61] for the differentiation of hESCs/hiPSCs into 
functional pancreatic b-like cells. More recently, 
Yabe et al. [63] used a six-stage protocol for the 
differentiation of human iPSCs to pancreatic b cells 
using defined culture media without feeders or serum. 
They showed that induction of definitive endoderm by 
a selective glycogen synthase-kinase-3 b inhibitor and 
spheroid formation at the final stage of differentiation 
are important for the generation of functional b-like 
cells. After the transplantation of these cells under 
the kidney capsule of streptozotocin-induced diabetic 
non-obese immunocompromised (NOD/SCID) mice, 
blood glucose levels gradually decreased over the next 
4 weeks; however, not in all transplanted animals 
[63]. Memon et al. [64] found that dissociation of 
densely formed definitive endoderm cells obtained 
from human iPSCs and re-plating them at low density, 
followed by a longer period of retinoic acid (RA) and 
FGF10 signaling resulted in a high yield of PDX1+/
NKX6.1+ pancreatic progenitors. Recently, a novel 
protocol for rapid and footprint-free differentiation of 
hESCs to endocrine cells by the lipofection technique 
was described by Ida et al. [65]. The authors introduced 
synthetic mRNAs (synRNAs) encoding transcription 
factors PDX1 and NKX6.1 by the lipofection reagent 
into hESCs and demonstrated that pancreatic endo-
crine hormones were highly expressed in cells trans-
fected with synRNA-PDX1 and synRNA-NKX6.1 at 
day 13, as shown by immunohistochemical staining of 
insulin, glucagon, and somatostatin in various popu-
lations of the obtained cells. The hESCs were able to 
differentiate into pancreatic endoderm cells within 
3 days, and within 7–9 days into multipotent pancreatic 
progenitors [65]. Since growth factors are costly com-
ponents of the culture media necessary for in vitro 
cell differentiation, Kondo et al. [66], after screening 
of 1250 small molecules, found that the addition of 
sodium cromoglicate facilitated the differentiation 
of endocrine precursors from multiple hiPSC/hESC 
lines and substantially increased the induction rate of 
insulin-positive cells.
Many other groups have modified culture con-
ditions and sets of small molecules used at the 
sequential stages to shorten the time of the in vitro 
differentiation of hESCs or hiPSCs into insulin-se-
creting b-like cells and to increase the efficiency of 
the procedures. The various chemical modulators of 
the sequential in vitro differentiation stages have been 
recently characterized [67–71]. 
Figure 2 shows the main stages of an idealized 
protocol for the differentiation of hESCs or hiPSCs 
into b-like cells and presents the key growth factors 
and other molecules that affect multiple signaling 
pathways at each differentiation step. These in vitro 
differentiation stages mimic the developmental events 
that take place during murine or human pancreato-
genesis and b cell lineage development. Thus, the 
first stage of transforming hESCs or hiPSCs into de-
finitive endoderm is based on mimicking Nodal and 
Wnt signaling pathways by activin A as well as IDE1 
and IDE2, small molecules that act synergistically 
with activin A [72]. High concentrations of activin 
A mimic the proendodermal role of Nodal during 
in vivo gastrulation, whereas Wnt3a ligand, involved 
in endodermal patterning in mammals, was later 
replaced by CHIR99021 shown to be more effective 
[73] for the induction of definitive endoderm marked 
by the expression of FOXA2, SOX17 and CXCR4 
(Fig. 2). The next step (for simplicity we omit here 
the intermediary stages of primitive gut tube and 
posterior foregut, as described in the original protocol 
by Rezania et al. [58]) is the formation of multipotent 
pancreatic progenitors (pancreatic endoderm) that is 
characterized by the expression of the key transcrip-
tion factors PDX1 and NKX6.1. The differentiation 
media contain retinoic acid (RA), which activates 
HOX genes during in vivo pancreatic and liver en-
doderm formation, cyclopamine and SANT1 (which 
inhibit Shh signaling and promote pancreatic lineage 
development), fibroblast growth factors such as FGF7 
and FGF10 (in mouse FGF10 promotes the expansion 
of the Pdx1-expressing endodermal cells), and Noggin, 
an inhibitor of BMP signaling that suppresses hepatic 
lineage differentiation. Moreover, activators of the 
protein kinase C (PKC), such as epidermal growth 
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factor (EGF) with nicotinamide (a poly(A-ribose) in-
hibitor), EGF with keratinocyte growth factor (KGF) 
or indolactam V (screened from over 4,000 chemicals 
(74)), and inhibitors of the BMP and Shh signaling (Shh 
inhibits the development of pancreatic endoderm in 
mouse) are also added to the culture media to increase 
the population of multipotent pancreatic progenitor 
cells (Fig. 2). The next stage, the generation of endo-
crine progenitors, is achieved in the presence of RA, 
EGF (required for branching morphogenesis during 
development of endocrine lineage in mouse pancreas 
[11]), triiodothyronine (T3, increases expression of 
neurogenin 3 necessary for b cell differentiation and 
maturation), betacellulin (EGF receptor ligand that 
maintains NKX6.1 expression [59]), heparin, vitamin 
C (prevents the formation of polyhormonal cells [58]), 
BMP receptor inhibitor (Alk5i II, activin receptor-like 
kinase 5 inhibitor II), and g-secretase inhibitor (sup-
presses Notch signaling). The differentiation of the 
endocrine progenitors into b-like cells is promoted by 
T3, vitamin E, betacellulin, heparin, Alk5 inhibitor, 
as well as Axl receptor tyrosine kinase (Axl) inhibitor 
and N-acetyl cysteine, which induce the expression of 
MAFA [58, 59] (Fig. 2). 
These shortly characterized multi-step protocols 
of the in vitro differentiation of hESCs or hiPSCs into 
b-like cells are technically complicated, costly, take 
usually a few weeks, and often suffer from low differ-
entiation efficiency, which is partially caused by the 
genetic variability of different hESC and hiPSC lines. 
To shorten the long differentiation procedures, Trott 
et al. [75] developed culture conditions by using feed-
er-based platform (mouse embryonic fibroblasts) that 
support long-term self-renewal of human multipotent 
pancreatic progenitors which express key pancreatic 
transcription factors, including PDX1 and SOX9, and 
exhibit transcriptomes closely related to their in vivo 
counterparts. These cells can be differentiated into 
glucagon- and insulin-expressing cells in vitro and 
in vivo. This type of approach offers a convenient 
alternative to pluripotent cells as a source of adult 
cell types for diabetes treatment and modeling of the 
development of human pancreas.
Southard et al. [76] created a pluripotent cell 
line derived from human primary pancreatic tissue 
by reprogramming the cells (without knowledge of 
their specificity) with non-integrating vectors, and 
generated definitive endoderm after a four-day dif-
ferentiation protocol. The selected SR1423 cell line 
was differentiated according to a simplified protocol 
to generate after 4 weeks populations with more than 
60% of insulin-expressing cells that secreted insulin in 
response to glucose and reversed diabetes in rodents. 
The authors suggest that after banking following 
the guidelines of Good Manufacturing Practice, the 
SR1423 is a candidate cell line for the production 
of insulin-secreting cells useful for the treatment of 
insulin-dependent diabetes.
Since the protocols of hESC or hiPSCs differenti-
ation into b cell lineage mimic the in vivo endocrine 
pancreas development, the expression of transcrip-
tions factors or surface markers at the corresponding 
in vitro stages has been used to validate the applied 
protocols. Fluorescence-activated cell sorting (FACS) 
with specific cell surface markers has been used for the 
isolation and further characterization of the human 
fetal pancreatic cells as well as for the characterization 
of in vitro differentiating hESCs/hiPSCs cells. The 
examples of surface markers used for FACS-sorting 
of pancreatic progenitor cells include CD142 (tissue 
factor, a marker of pancreatic endodermal cells that 
also labels additional cell types) [77], CD24 (a marker 
for PDX1-expressing pancreatic progenitors derived 
from hESCs) [78], and GP2. GP2, a glycoprotein 
present in pancreatic secretory granules, expressed 
together with the key transcription factors NKX6.1 and 
PTF1a, was shown to be a cell surface marker of human 
multipotent pancreatic progenitors [79–80]. Ramond et 
al. [81] investigated human fetal pancreatic epithelial 
cells by FACS analysis using a combination of the cell 
surface markers GP2, ECAD (also known as CDH1, 
i.e. cadherin 1), CD142, and SUSD2 (Sushi domain 
containing 2, a marker used to enrich NEUROG3-posi-
tive cell population from hPSC-derived pancreatic cells 
and the human fetal pancreas [82]). They identified 
distinct endocrine populations at different stages of 
their development (pancreatic progenitors, endocrine 
progenitors, and endocrine cells) and showed that 
a subset of the GP2-positive cells undergoes endocrine 
differentiation by down-regulating GP2 and CD142 
and up-regulating the expression of NEUROG3, 
a marker of endocrine lineage differentiation [81]. The 
same group improved the purity of the cell populations 
isolated from three human fetal pancreata at G9w by 
applying an additional surface marker, CD133 (promi-
nin 1, often expressed on adult stem cells), to exclude 
ductal cells, along with using granularity to distinguish 
endocrine cells [83]. The transcriptional profiling of the 
isolated cell populations at the single-cell level using 
qPCR showed that, at a single time point, different 
steps of the endocrine differentiation can be identi-
fied. Moreover, this approach enabled to benchmark 
the pancreatic cell types produced in vitro from one 
hESCs and two hiPSCs cell lines using an established 
endocrine-biased differentiation protocol [83]. Fur-
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ther studies of single-cell transcriptomes of mouse 
and human progenitors at different steps of pancreas 
development will allow to capture intermediate stages 
of differentiation, increase the efficacy of the in vitro 
generation of b cell progenitors, and discover factors 
that will improve the functionality of the b-like cells. 
Validation of the b-like  
cells generated in vitro
Although the b-like cells show the morphological 
and some of the functional characteristics of the bona 
fide adult b cells, they must be regarded as immature b 
cells. The comparison of single cell transcriptomes and 
proteomes of b-like cells generated from hiPSCs with 
those of mature b cells revealed the lack of some mol-
ecules present in the bona fide b cells [84]. Numerous 
tests have been applied to characterize the phenotype 
of the in vitro generated b-like cells. They include the 
expression of specific surface molecules to perform 
FACS sorting, immunohistochemistry to detect insulin 
or C peptide, marker gene analysis by real-time PCR, 
the presence of potassium channels Kir6.1 and Kir6.2 
and the ATP-binding cassette channel Sur1 which are 
necessary for insulin secretion [85]. Coupled to GSIS 
(glucose-stimulated insulin secretion) assessment, the 
presence of these proteins should be used in order to 
establish optimal b-like cells’ response to glucose. The 
functional assays include testing of the extent of glu-
cose-stimulated insulin secretion in terms of its amount 
and stimulation index (i.e. the ratio of insulin secretion 
levels between low- and high-glucose concentrations), 
fluctuations of Ca2+ intracellular levels, or secretion of 
C-peptide. Initially, the hESC-derived b-like cells pre-
sented suppressed glucose-stimulated insulin secretion 
[56], and in response to a rapid increase of glucose 
concentration they did not reproduce the high ampli-
tudes of fast changes of Ca2+ concentrations that are 
a hallmark of the mature b cells isolated from human 
pancreatic islets [84, 85].
Concluding remarks
The ultimate target of in vitro produced b-like cells is 
their phenotypic and functional similarity to the authen-
tic b cells of human pancreas. Despite the continuous 
improvements in the differentiation protocols of human 
ESCs or hIPSCs for scalable in vitro generation of b-like 
cells, the time is not yet ready for their use as an alterna-
tive diabetes treatment. It has been shown that there are 
differences between different hESCs and hiESCs in their 
transcriptomic profiles and efficacy of reprogramming 
into b-like cell progenitors [86]. Moreover, the b-like 
cells rarely present pure populations since they are 
often contaminated by other endocrine cell types and 
are sometimes polyhormonal. Thus, reproducibility and 
standardization of the in vitro differentiation processes 
present essential requirements that have to be clearly 
defined for the acceptance of the b-like cells for future 
therapies by health regulatory authorities. There are 
important ethical concerns associated with the use of 
embryonic cells from destroyed human embryos. Also 
the use of human induced pluripotent stem cell lines 
carries the risk of transmitting possible disease heredi-
tary traits from a donor.
It has been demonstrated that in vitro generation of 
b-like cells is possible also with iPSCs derived from pa-
tients with T1D and T2D [87–89] and maturity-onset 
diabetes of the young [90–92]. It is hoped that genera-
tion of hiPSCs derived e.g. from fibroblasts of patients 
with diabetes [93] will improve our understanding of 
the underlying genetic abnormalities, provide targets 
for high-throughput screening of thousands of mole-
cules as possible therapeutics, and offer personalized 
treatment by autologous transplantation, since the 
allogenic transplantation of hPSC-derived b-like 
cells is likely to induce an immune response. The 
advancements in the engineering of encapsulation 
devices that allow for the contact of the transplanted 
cells with the invading blood vessels but protect them 
from contact with the immune cells provide hope that 
these obstacles could be overcome in the near future 
[94–97]. Obviously, we need more clinically relevant 
information from the ongoing clinical trials of the di-
abetes treatment with hESC- or hiPSC-derived b-like 
cells regarding the functionality of the transplanted 
cells and immune reactivity of the recipients. Since 
all these important problems are also relevant for the 
b-like cells obtained from in vitro direct transdiffer-
entiation of differentiated somatic cells, they will be 
discussed in our next review paper. 
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